Restructuring |
3 Months Ended |
|---|---|
Mar. 31, 2025 | |
| Restructuring | |
| Restructuring | Note 4. Restructuring On May 8, 2024, the Company took actions as part of its continued efforts to preserve cash and prioritize investment in its core clinical programs. The Company reduced its workforce by approximately 15% and notified impacted employees on May 8, 2024. All related restructuring costs were paid in the second quarter of 2024. On September 17, 2024, the Company reduced its workforce by an additional 28% to extend its cash runway and prioritize clinical development of BXCL501. The Company completed the Clinical Prioritization in October 2024, paid $475 of the related costs during the first quarter of 2025, and expects to pay approximately $128, the remaining costs, in the second quarter of 2025, which are included in Accrued Expenses on the Condensed Consolidated Balance at March 31, 2025. |